Interferon beta 1a(The University of Southampton)

DUBLIN, July 14, 2023 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. With an extensive focus on 65+ companies and 70+ pipeline drugs, this report provides a detailed analysis of the current scenario and growth prospects across the indication. The report encompasses a comprehensive overview of the pipeline drug profiles, covering both clinical and nonclinical stage products. Additionally, it includes a thorough assessment of therapeutics, considering product type, stage, route of administration, and molecule type. Inactive pipeline products in this space are also highlighted, providing a holistic view of the COPD pipeline landscape. To provide a comprehensive understanding, this report outlines the present scenario and growth prospects in the COPD field. It offers detailed insights into the disease overview and treatment guidelines for Chronic Obstructive Pulmonary Disease, setting the stage for a deeper exploration of the pipeline landscape. Furthermore, the report delves into the commercial assessment and clinical assessment of the pipeline products under development. It provides detailed descriptions of each drug, including their mechanisms of action, clinical studies, NDA approvals (if any), and comprehensive product development activities. This encompasses technology, COPD collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant product-related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Chronic Obstructive Pulmonary Disease Emerging Drugs Benralizumab: AstraZeneca Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Dupilumab: Sanofi Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development. Tezepelumab: Amgen Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease. SNG001: Synairgen SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD. GSK3923868: GlaxoSmithKline GSK3923868, is a PI4kb inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease. Chronic Obstructive Pulmonary Disease: Therapeutic Assessment This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Chronic Obstructive Pulmonary Disease There are approx. 65+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca. Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Intramuscular Molecule Type Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Product Type Chronic Obstructive Pulmonary Disease Report Insights Chronic Obstructive Pulmonary Disease Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Key Players Sanofi AstraZeneca Amgen Synairgen GlaxoSmithKline Eisai Meridigen Biotech Chiesi EmeraMed Limited Verona Pharma Tetherex Pharmaceuticals Mereo BioPharma Key Products Lemborexant UMC119-06 CHF5259 Emeramide Ensifentrine SNG001 GSK3923868 Benralizumab Dupilumab Tezepelumab SelK2 BCT197 For more information about this clinical trials report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

曾经一度被寄予厚望的新冠特效药，在全球疫情逐渐消退的当下，却接连爆出“翻车”的消息。近日，默沙东发布了Molnupiravir两项真实世界临床证据和一项非临床研究进展结果。其中一项由牛津大学资助的开放、前瞻性真实世界PANORAMIC的研究数据初步分析结果显示，在英国进行的针对＜65岁接种疫苗的成年人中，就减少住院人数和死亡人数方面而言，Molnupiravir添加到常规护理与仅使用常规护理相比没有任何差异，到第28天的住院和死亡的发生率，两组均为0.8%。通俗地说，这药吃了个寂寞，和安慰剂没有任何差别。Molnupiravir是全球首款获得授权的口服抗新冠病毒药物，属于新型核糖核苷类似物前药，用于治疗经SARS-CoV-2检测呈阳性、确诊轻度至中度新冠病毒病（新冠肺炎）、且有潜在重症（包括住院或死亡）风险的成年患者。这款由默沙东研发上市的抗新冠药物，已经在全球超过40多个国家和地区上市，就在9月28日，默沙东与国药集团签署协议，将Molnupiravir在中国的经销权和独家进口权授予国药集团。全球另一款抗新冠病毒的明星药物，由辉瑞研发上市的Paxlovid，也发现了疗效欠佳的临床证据。今年8月，在《新英格兰医学杂志》上发表的一项研究显示，对于40-60岁的患者来说，在接受Paxlovid治疗与不接受Paxlovid治疗的患者中，住院率为每10万人15.2例VS每10万人15.8例，二者相差并不大。但是研究也显示，Paxlovid对老年人确实有一定效果。具体来说，在参与研究的4.3万名65岁以上的新冠患者中，接受Paxlovid治疗的患者住院率为每10万人14.7例，而在未经治疗的患者住院率每10万人58.9例。此外，对Paxlovid还有另外一个更严重的质疑，就是一些患者在停药后，新冠症状出现了反弹，比如包括美国总统拜登、辉瑞CEO艾伯乐在内，都曾在服药后发生了“复阳”症状。除了以上两款已上市的知名药物开始“爆雷”以外，几款正在研发中的抗新冠病毒药物也纷纷传出坏消息。10月15日，日本富士胶片公司正式对外宣布，已决定停止研发其新冠治疗药物Avigan(法匹拉韦)，原因是在对患者的临床试验中未能确认药物的有效性，以及重症率较低的Omicron毒株成为主流，令口服药的需求急剧减少。富士胶片从去年4月展开法匹拉韦的临床试验，原先目标是招募316名患者，但直至今年3月为止，只有84名患者进入临床试验，而且分析了受试者的数据后，显示法匹拉韦未能对预防重症产生有意义的效用。在今年更早的2月21日，美国Synairgen公司也宣布，SNG001治疗新冠肺炎住院患者的临床III期SPRINTER研究，未达到其主要或关键次要疗效终点，宣告研发失败。受此消息影响，Synairgen公司股价下跌84%。关于已获批药物上市后表现不佳，以及在研药物的失败，学术界有多种解释，主要的原因集中在新冠病毒株的变异；有专家指出，以病毒的某个单分子为靶点的小分子口服药对付不断变异的病毒，出现力不从心、效力欠佳的情况可以说是必然的。如果抗新冠病毒小分子药物的时效性如此之短，甚至在药物上市的时刻，就是治疗效力开始大幅衰减的时刻，那么抗新冠病毒小分子药物的临床意义，可能要大打折扣。目前全球已有4款新冠口服药上市，其中真实生物的阿兹夫定和辉瑞的Paxlovid两款药物，已经在中国获批上市。此外还有礼来和Incyte的巴瑞替尼老药新用，用于需要补充氧的新冠患者，于2021年4月在日本上市，在美国获批EUA；默沙东的莫奈拉韦最早于2021年11月在英国获批上市，随后在日本上市、在美国获批EUA，目前已向中国提交NDA。再看中国市场，目前虽然只有真实生物的阿兹夫定一款国产药物获批，但是国内还有一支浩浩荡荡的新冠特效药研发大军，包括：君实生物、云顶新耀、先声药业、歌礼制药、科兴制药、开拓药业、盟科药业、众生睿创、盘龙药业、广生中霖、广生堂，等等。希望他们可以创造奇迹。来源 | 医药投资部落（药智网获取授权转载）撰稿 | 医药投资部落责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。— Tips —如果您有医药行业相关的线索或对医药政策、研发创新、资本市场、产业发展有深度观察欢迎投稿给我们马老师 18323856316（同微信）邮箱：maxuelian@yaozh.com发现“分享”和“赞”了吗，戳我看看吧